Now live: European new issue coverage and historical data, for free. → Explore All Content & Delivery Channels
Log In
No results found for "".

Commentary & Deal Flow

PRICED: Cerba E300m 3.50% sr sec at 99.75, E200m 5% sr unsec at 100

HYC European Market: Deal Flow - General

Cerba Healthcare (CERBA) EUR500m 144A/Reg S notes 2-part. Via DB (sole physical)/GS/JPM/UBS jt lead books/BNP/CA/HSBC/Mediobanca/Mizuho/Nomura/UniCredit jt books. No reg rights. List Lux. NY law. Settles 10/26 (T+4).

- Chrome Bidco SAS EUR300m add-on to its 3.50 sr sec notes due 05/31/28 (6.5y). NC2.5 (05/31/24) (MWC B+50bp), then at 101.750, 100.875, 100. Equity claw: 2.5y 40% at 103.50. Special call: 10% per year the first 2.5 years at 103. B1/B (stable/stable). Reg S ISIN: XS2343000241. Immediately 144A fungible (Reg S after 40 days) with the EUR420m issue priced 05/12/21. Px talk: 99.25-99.75. Final terms: EUR300m 3.50% add-on at 99.75. Priced: 3.50% add-on at 99.75, 3.54% YTM. +390bp vs DBR 0.25% 08/15/28.

- Chrome Holdco SAS EUR200m add-on to its 5.00% sr unsec notes due 05/31/29 (7.5y). NC2.5 (05/31/24) (MWC B+50bp), then at 102.50, 101.25, 100. Equity claw: 2.5y 40% at 105.00. Caa1/CCC+ (stable/stable). Reg S ISIN: XS2343001991. Immediately 144A fungible (Reg S after 40 days) with the EUR325m issue priced 05/12/21. Px talk 99.50-par. Final terms: EUR200m 5.00% add-on at 100. Priced: 5.00% add-on at 100, 5.00% YTM. +528bp vs DBR 0% due 08/15/29.

Roadshow Mon-Tues (investor call at 11am UKT Mon). Books closed at 12pm UKT today. UOP: along with EUR350m (up from EUR300m) term loan B add-on via GS/JPM/UBS+, to fund the acquisition of Lifebrain from Investindustrial for around EUR1.2bn enterprise value (EUR675m equity purchase and EUR520m debt refi) (EUR50m TLB upsize for cash on the B/S). The equity sponsors, EQT and PSP Investments, will contribute EUR466m in new equity. Biz: an international network of medical biological laboratories providing medical diagnostic services. HQ: Issy-les-Moulineaux, France. (Acquisition announced 07/21/21).

We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.
By continuing, you agree to FINSIGHT's Terms of Use and Privacy Policy.